Robert Hombach
Directeur/Membre du Conseil chez BIOMARIN PHARMACEUTICAL INC.
Fortune : 3 M $ au 31/05/2024
Profil
Robert J.
Hombach is an Independent Director at BioMarin Pharmaceutical, Inc., a Director at EDGe Surgical, Inc., an Independent Director at Embecta Corp., and an Industry Advisor at Agent Capital LLC.
He was previously an Independent Director at CarMax, Inc. from 2018 to 2022, a Director at Naurex, Inc., a Director at Loyola University Health System, the President & Director at Baxter International Foundation, and an Independent Director at Aptinyx, Inc. from 2018 to 2023.
He also served as the Chief Financial Officer & Vice President at Baxter International, Inc. from 2011 to 2015 and as the Executive VP, Chief Operations & Financial Officer at Baxalta, Inc. from 2015 to 2016.
Hombach received his undergraduate degree from The University of Colorado in 1988 and his MBA degree from Kellogg School of Management in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/05/2024 | 35 220 ( 0,02% ) | 3 M $ | 31/05/2024 | |
EMBECTA CORPORATION
0,04% | 07/02/2024 | 24 904 ( 0,04% ) | 308 062 $ | 31/05/2024 |
APTINYX INC
0,34% | 24/04/2023 | 229 100 ( 0,34% ) | 21 994 $ | 31/12/2023 |
Postes actifs de Robert Hombach
| Sociétés | Poste | Début |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Directeur/Membre du Conseil | 29/09/2017 |
| EMBECTA CORP. | Directeur/Membre du Conseil | 20/03/2022 |
EDGe Surgical, Inc.
 EDGe Surgical, Inc. Electronic Equipment/InstrumentsElectronic Technology EDGe Surgical, Inc. develops orthopedic and spine surgery instruments. The company was founded in 2015 and is headquartered in Chicago, IL. | Directeur/Membre du Conseil | - |
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Robert Hombach
| Sociétés | Poste | Fin |
|---|---|---|
| APTINYX | Directeur/Membre du Conseil | 30/06/2023 |
| CARMAX, INC. | Directeur/Membre du Conseil | 28/06/2022 |
| BAXALTA INC | Directeur Financier/CFO | 01/07/2016 |
| BAXTER INTERNATIONAL INC. | Directeur Financier/CFO | 01/07/2015 |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Directeur/Membre du Conseil | - |
Formation de Robert Hombach
| The University of Colorado | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| CARMAX, INC. | Retail Trade |
| APTINYX | Health Technology |
| EMBECTA CORP. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Loyola University Health System
 Loyola University Health System Hospital/Nursing ManagementHealth Services Loyola University Health System engages in the provision of healthcare services. It offers primary care, surgical, digestive health programs, orthopedics, neurology and neurosurgery, transplant, and other medical services. The company is headquartered in Maywood, IL. | Health Services |
| Baxter International Foundation | |
EDGe Surgical, Inc.
EDGe Surgical, Inc. Electronic Equipment/InstrumentsElectronic Technology EDGe Surgical, Inc. develops orthopedic and spine surgery instruments. The company was founded in 2015 and is headquartered in Chicago, IL. | Electronic Technology |
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Finance |
